MedPacto Appoints Timothy Allen as Vice President of Global Clinical Affairs

Global Pharmaceutical Company's 20 Years of Clinical Experience Know-How
Accelerating 'Bactosertip' Global Phase 3 Clinical Trials

Dr. Timothy Allen, recruited as Vice President of Clinical Affairs at MedPacto's U.S. subsidiary.

[Asia Economy Reporter Kwanju Lee] MedPacto announced on the 24th that it has recruited global clinical expert Dr. Timothy R. Allen as the Vice President of Clinical Affairs at its U.S. subsidiary, MedPacto Therapeutics.

Vice President Allen is an oncology clinical expert with over 20 years of clinical experience at global pharmaceutical companies including Merck Germany, BMS, GSK, Roche, AstraZeneca, and Sanofi. Recently, he served as Vice President of Clinical Development at Karyopharma, a publicly listed global biotech company focused on oncology drug development.

In addition to Vice President Allen, MedPacto has recruited Director Ebla Ali Ibrahim, who has extensive experience in regulatory affairs (RA) related to drug registration, and Senior Manager Cori Greutter, a clinical project manager, as members of the clinical development team at its U.S. subsidiary.

Director Ibrahim worked for 11 years at the U.S. Food and Drug Administration (FDA) in the Center for Drug Evaluation and Research (CDER) and the Center for Biologics Evaluation and Research (CBER), and has extensive experience with global CROs. Senior Manager Greutter has experience working at global CROs and global biopharma companies. All have rich experience working with the U.S. FDA, which is expected to greatly contribute to MedPacto’s global clinical strategy going forward.

MedPacto is conducting global clinical trials in combination therapy with the TGF-β inhibitor 'Vactosertib' in collaboration with global pharmaceutical companies. It is preparing for a global Phase 3 clinical trial of 'Vactosertib + Keytruda' (colorectal cancer) with MSD in the U.S., and is conducting a global Phase 2 clinical trial of 'Vactosertib + Imfinzi' (bladder cancer) with AstraZeneca.

The U.S. clinical team led by Vice President Allen will be responsible for the overall clinical strategy and global clinical trials of MedPacto’s TGF-β inhibitor 'Vactosertib.' They will also be responsible for the global clinical strategy of next-generation candidate substances following Vactosertib.

A MedPacto official said, “At a time when we are expanding global clinical trials of the TGF-β inhibitor 'Vactosertib,' the recruitment of a global clinical expert is expected to accelerate not only clinical trials with the U.S. FDA but also the advancement of global clinical development.”

This content was produced with the assistance of AI translation services.